Product Description
Axitinib is used alone to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in people who have not been treated successfully with another medication. Axitinib is used in combination with avelumab (Bavencio) or pembrolizumab (Keytruda) to treat advanced renal cell carcinoma. Axitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a612017.html)
Mechanisms of Action: PGFRb Antagonist,VEGFR1 Antagonist,VEGFR2 Inhibitor,VEGFR3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Renal Cell Carcinoma | Oncology Unspecified | Kidney Diseases
Known Adverse Events: Hypertension | Dysphonia | Asthenia | Constipation | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 38
Highest Development Phases
Phase 3: Kidney Cancer|Kidney Diseases|Neovascular age-related macular degeneration|Renal Cell Carcinoma|Wet Macular Degeneration
Phase 2: Abnormalities, Multiple|Anal Cancer|Carcinosarcoma|Cervical Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Endometrial Cancer|Fallopian Tube Cancer|Hodgkin Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Melanoma|Mucinous Adenocarcinoma|Multiple Myeloma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Non-Small-Cell Lung Cancer|Oncology Unspecified|Ovarian Cancer|Papillary Carcinoma|Small Cell Carcinoma|Small Cell Sarcoma|Thymoma|Uterine Cancer|Vaginal Cancer|Vision, Low|Vulvar Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CARE1 | P3 |
Recruiting |
Renal Cell Carcinoma|Kidney Cancer |
2032-05-05 |
|
| SAMURAI | P2 |
Recruiting |
Renal Cell Carcinoma |
2028-06-15 |
|
| 2021-006430-39 | P2 |
Active, not recruiting |
Renal Cell Carcinoma |
2028-06-01 |
|
| ProTarget | P2 |
Active, not recruiting |
Oncology Unspecified |
2028-04-28 |